510(k) Report

510(k) · Cleared

Cleared

Fasttake Compact Blood Glucose Monitoring System

K990939510(k) SpecialCleared Apr 20, 199929-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Selfcare, Inc. · CGA Glucose Oxidase, Glucose

Cleared on Apr 20, 1999 as substantially equivalent to K970707 (Selfcare, Inc., 1997) after a 29-day review. Its family tree reaches back 2 generations to 1995. 1 later device descends from it.

Decided
Apr 20, 1999
Review
29 days
Class
Class II
Product code
CGA
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K945887 (1995). 3 ancestors in all. 1 later device descends from it, 1 citing it directly.

Other ancestors, by year clearedDescendants, by year cleared 1996: 1 other ancestor1999: 1 descendant clearedK945887 · Precision Q I D Blood Glucose Test Strips · Medisense, Inc. · 1995K970707 · Elect II Blood Glucose Monitoring System · Selfcare, Inc. · 19971995200020052010201520202025
Other ancestors, by generationDescendants, by generation 2 generations back: 1 other ancestor 1 generation forward: 1 descendant K970707 · Elect II Blood Glucose Monitoring System · Selfcare, Inc. · 1997K945887 · Precision Q I D Blood Glucose Test Strips · Medisense, Inc. · 19950
  1. Root · 2 generations backK945887 Precision Q I D Blood Glucose Test StripsMedisense, Inc. · 1995
  2. 1 generation backK970707 Elect II Blood Glucose Monitoring SystemSelfcare, Inc. · 1997
  3. This deviceK990939 Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc. · 1999
  4. Descendant · cites it directly · 0 of its ownK993632 Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc. · 1999

Most influential descendants

Showing 1 of 1 · See all
  • K993632Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc. · 1999 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K945887Precision Q I D Blood Glucose Test StripsMedisense, Inc.1995—
−1K970707Elect II Blood Glucose Monitoring SystemSelfcare, Inc.1997—
0 (this device)K990939Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc.1999—
+1K993632Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc.1999—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199610

Descendants by year cleared

Year clearedDevicesWith a Class I recall
199910
FIG. 1 — Lineage of K990939, 1995–1999Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CGA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CGA device

  1. #1 K252488 ABL90 FLEX PLUS Systemscore 12.8 · 6 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K970707Elect II Blood Glucose Monitoring System
Summary page 1
…from the predicate device, FastTake® Compact Blood Glucose Monitoring System, was cleared for use in the United States as the Elect II Blood Glucose Monitoring System by K970707. Both the modified and unmodified FastZake® Blood Glucose Monitoring Systems were developed and are controlled Selfcare, Inc. in…
Selfcare, Inc.1997—

Also cleared against K970707: 1 other device →

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K993632Fasttake Compact Blood Glucose Monitoring SystemSelfcare, Inc.19990

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 2.2 years on median.
  • None of the 3 ancestors has a recall.
  • Of its descendants, K993632 (Selfcare, Inc., 1999) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K970707.

How does its category compare?

All CGA devices

CGA Glucose Oxidase, Glucose: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · CGA

2in 2024

2007: 72008: 62009: 102010: 82011: 92012: 102013: 32014: 52015: 42016: 42017: 22018: 22019: 22020: 22021: 12022: 12023: 42024: 22026 (partial year): 1
2007high 10 (2009) · low 0 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGA

249in 2023

2007: 122 days median2008: 56 days median2009: 155 days median2010: 122 days median2011: 217 days median2012: 123 days median2013: 441 days median2014: 265 days median2015: 150 days median2016: 157 days median2023: 249 days median
2007high 441 (2013) · low 56 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CGA

3in 2023

2007: 22008: 22009: 42010: 62011: 32013: 32014: 22015: 6, 2 Class I2016: 22019: 12023: 3
2007high 6 (2010) · low 0 (2012)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · CGA

59in 2025

2007: 292008: 372009: 752010: 1722011: 4232012: 2332013: 1722014: 1222015: 1552016: 362017: 922018: 692019: 1162020: 682021: 482022: 2722023: 1,1412024: 2662025: 59
2007high 1,141 (2023) · low 29 (2007)2025

MAUDE reports naming product code CGA, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20077122229
2008656237
200910155475
201081226172
201192173423
2012101230233
201334413172
201452652122
201541506 (2)155
20164157236
20172—092
20182—069
20192—1116
20202—068
20211—048
20221—0272
2023424931,141
20242—0266
20250—059
20261—0—

What is it indicated for?

The FastTake® Compact Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood. The FastZake® System is intended for use outside the body (in vitro diagnostic use) by diabetics at home as an aid to monitor the effectiveness of diabetes control.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K990939: Fasttake Compact Blood Glucose Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K990939

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026